Evidence map›Paper›PMID 26000857›Full record

ArticlePLoS genetics2015

Rescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model.

Shamim H Rahman, Johannes Kuehle, Christian Reimann, Tafadzwa Mlambo, Jamal Alzubi, Morgan L Maeder, Heimo Riedel, Paul Fisch, Tobias Cantz, Cornelia Rudolph and 4 more

Abstract read
In one paragraph

Article in PLoS genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Modeling MyD88 DeficiencyFrontiers in immunology · 2020
    Article
  5. Article
  6. Article
  7. Review
  8. Genome-editing Technologies for Gene and Cell Therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2016
    Review
  9. Current Progress in Therapeutic Gene Editing for Monogenic Diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shamim H RahmanInstitute for Cell and Gene Therapy, University Medical Center Freiburg, Freiburg, Germany; Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Johannes KuehleInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Christian ReimannInstitute for Cell and Gene Therapy, University Medical Center Freiburg, Freiburg, Germany; Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany.
Tafadzwa MlamboInstitute for Cell and Gene Therapy, University Medical Center Freiburg, Freiburg, Germany; Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany; Spemann Graduate School of Biology and Medicine (SGBM), University of Freiburg, Freiburg, Germany.
Jamal AlzubiInstitute for Cell and Gene Therapy, University Medical Center Freiburg, Freiburg, Germany; Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Morgan L MaederMolecular Pathology Unit, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America; Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America.
Heimo RiedelInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany; Department of Biochemistry and Mary Babb Randolph Cancer Center, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, West Virginia, United States of America.
Paul FischInstitute of Pathology, University Medical Center Freiburg, Freiburg, Germany.
Tobias CantzTranslational Hepatology and Stem Cell Biology, REBIRTH cluster of excellence, Hannover Medical School, Hannover, Germany.
Cornelia RudolphInstitute for Cellular and Molecular Pathology, Hannover Medical School, Hannover, Germany.
Claudio MussolinoInstitute for Cell and Gene Therapy, University Medical Center Freiburg, Freiburg, Germany; Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany.
J Keith JoungMolecular Pathology Unit, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America; Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America.
Axel SchambachInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Toni CathomenInstitute for Cell and Gene Therapy, University Medical Center Freiburg, Freiburg, Germany; Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.

Funding

ADVANCING ZINC FINGER NUCLEASES FOR TARGETED GENOME MANIPULATIONR01GM088040 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI JOUNG, J. KEITH, PETERSON, RANDALL T · 2009 to 2016
$4.5M
NIGMS NIH HHS R01 GM088040
6 · The paper itself

Abstract

In vitro disease modeling based on induced pluripotent stem cells (iPSCs) provides a powerful system to study cellular pathophysiology, especially in combination with targeted genome editing and protocols to differentiate iPSCs into affected cell types. In this study, we established zinc-finger nuclease-mediated genome editing in primary fibroblasts and iPSCs generated from a mouse model for radiosensitive severe combined immunodeficiency (RS-SCID), a rare disorder characterized by cellular sensitivity to radiation and the absence of lymphocytes due to impaired DNA-dependent protein kinase (DNA-PK) activity. Our results demonstrate that gene editing in RS-SCID fibroblasts rescued DNA-PK dependent signaling to overcome radiosensitivity. Furthermore, in vitro T-cell differentiation from iPSCs was employed to model the stage-specific T-cell maturation block induced by the disease causing mutation. Genetic correction of the RS-SCID iPSCs restored T-lymphocyte maturation, polyclonal V(D)J recombination of the T-cell receptor followed by successful beta-selection. In conclusion, we provide proof that iPSC-based in vitro T-cell differentiation is a valuable paradigm for SCID disease modeling, which can be utilized to investigate disorders of T-cell development and to validate gene therapy strategies for T-cell deficiencies. Moreover, this study emphasizes the significance of designer nucleases as a tool for generating isogenic disease models and their future role in producing autologous, genetically corrected transplants for various clinical applications.

Indexed as

Cell DifferentiationSignal TransductionAnimalsDisease Models, AnimalDNA-Activated Protein KinaseDNA-Binding ProteinsFibroblastsGenomeGenotyping TechniquesHEK293 CellsHumansInduced Pluripotent Stem CellsMaleMiceNIH 3T3 CellsNuclear ProteinsDNA-Activated Protein KinaseDNA-Binding ProteinsNuclear ProteinsPrkdc protein, mouseProtein Kinases

Identifiers

PMID26000857
PMCPMC4441453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.